Table 2

Results of virological and genotypic resistance testing by cohort

Cohort M12

Cohort M24


HIV RNA ≥ 1,000 copies/ml (%)

25

50


Available genotypic resistance (%)

20 (80.0)

42 (84.0)


Wild-type virus (%)

6 (30.0)

10 (23.8)

Resistance to ≥ 1 ARV drug (%)

14 (70.0)

32 (76.2)

Resistance to EFV and NVP (%)

3 (15.0)

1 (2.4)

Resistance to 3TC, EFV, and NVP (%)

9 (45.0)

22 (52.4)

Extensive resistance* (%)

2 (10.0)

9 (21.4)


ARV, antiretroviral; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine

*Resistance to EFV, NVP, 3TC, stavudine, zidovudine, or tenofovir, and didanosine, or multidrug resistance.

Ahoua et al. BMC Infectious Diseases 2009 9:81   doi:10.1186/1471-2334-9-81

Open Data